MDT-AP-1340
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 27
- os_event
- false
- age_years
- 5
- sex
- F
- new_clusters
- C1
- umap1_2d
- 4.833989941
- umap2_2d
- 0.366041549
- umap1_3d
- 0.654177553
- umap2_3d
- -3.876155955
- umap3_3d
- -1.104784992
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.440
- INTERFERON_GAMMA_RESPONSE+0.390
- IL6_JAK_STAT3_SIGNALING+0.280
- ANGIOGENESIS+0.250
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.240
- IL2_STAT5_SIGNALING+0.220
- APICAL_JUNCTION+0.200
- INFLAMMATORY_RESPONSE+0.200
- NOTCH_SIGNALING+0.200
- TGF_BETA_SIGNALING+0.200
Top 10 suppressed
- E2F_TARGETS-0.520
- G2M_CHECKPOINT-0.440
- MYC_TARGETS_V1-0.420
- SPERMATOGENESIS-0.260
- DNA_REPAIR-0.250
- PANCREAS_BETA_CELLS-0.250
- PROTEIN_SECRETION-0.180
- ANDROGEN_RESPONSE-0.160
- HEDGEHOG_SIGNALING-0.160
- UV_RESPONSE_UP-0.160
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MDT-AP-1209 | Med | Medulloblastoma | 0.818 |
| 2 | MDT-AP-0400 | Med | Medulloblastoma | 0.817 |
| 3 | R139 | — | — | 0.799 |
| 4 | TCGA-FD-A3SQ-01A-21R-A22U-07 | — | — | 0.796 |
| 5 | 6bf9821d-da67-470f-9650-69d05b056166 | — | — | 0.788 |
| 6 | TCGA-XF-A9SK-01A-11R-A42T-07 | — | — | 0.787 |
| 7 | MDT-AP-0379 | Med | Medulloblastoma | 0.785 |
| 8 | TCGA-D8-A73W-01A-22R-A352-07 | — | B | 0.785 |
| 9 | BS_TQ5QHR17 | Neurofibroma | — | 0.775 |
| 10 | SRR22247245 | — | cohortMD2 | 0.774 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.440 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.390 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.250 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.240 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.200 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.200 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.200 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.190 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.170 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.150 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.130 | Idelalisib | — uncovered |
| MYOGENESIS | 0.130 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.120 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.120 | Inavolisib | — uncovered |
| COAGULATION | 0.110 | Binimetinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.070 | Idelalisib | — uncovered |
| APOPTOSIS | 0.060 | Idelalisib | — uncovered |